{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:12:38Z","timestamp":1793301158572,"version":"4.5.0"},"reference-count":54,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hist Psychiatry"],"published-print":{"date-parts":[[2007,3]]},"abstract":"<jats:p>Clozapine is known as the first `atypical' medication and is effective in people who have treatment-resistant schizophrenia. Its 1990 emergence in the USA was marked by considerable controversy over its high cost, due in large part to having been both the first new antipsychotic medication to come to market in over a decade and the need for comprehensive safety monitor ing within a decentralized health system. This paper traces the histor y of clozapine's discover y and development in Europe, its part in the 1975 Finnish agranulocytosis scare, and its subsequent volatile emergence in the USA. Analyses examine peripheral forces at the time, particularly the influence of political, corporate, medical and societal forces which shaped its market course.<\/jats:p>","DOI":"10.1177\/0957154x07070335","type":"journal-article","created":{"date-parts":[[2007,4,16]],"date-time":"2007-04-16T10:18:24Z","timestamp":1176718704000},"page":"39-60","source":"Crossref","is-referenced-by-count":245,"title":["The history of clozapine and its emergence in the US market"],"prefix":"10.1177","volume":"18","author":[{"given":"John","family":"Crilly","sequence":"first","affiliation":[{"name":"University of Rochester, NY, Department of Psychiatry, 300 Crittenden Blvd, Rochester,\rNY 14642, USA,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2007,3,1]]},"reference":[{"key":"atypb1","doi-asserted-by":"crossref","unstructured":"Adams, M.E., Chang, H. and Frazier, H.S. (1995) Clozapine therapy for schizophrenia. In J. D. Graham and J. B. Wienert (eds), Risk vs. Risk: Tradeoffs in Protecting Health and the Environment (Cambridge, MA: Harvard University Press), 53\u201471.","DOI":"10.4159\/9780674037878-005"},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1977.tb00224.x"},{"key":"atypb3","doi-asserted-by":"publisher","DOI":"10.1007\/BF00606410"},{"key":"atypb4","first-page":"5","volume":"9","author":"Ayd, F.J.","year":"1974","journal-title":"Newsletter"},{"issue":"11","key":"atypb5","first-page":"746","volume":"324","author":"Baldessarini, R.J.","year":"1991","journal-title":"Medicine"},{"key":"atypb6","volume-title":"Personal interview by author, 3 Aug","author":"Caine, E.D.","year":"2005"},{"key":"atypb7","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.136.3.317"},{"key":"atypb8","first-page":"899","volume":"256","author":"Chirico, A.","year":"1957","journal-title":"Medicine"},{"issue":"1","key":"atypb9","first-page":"138","volume":"19","author":"Claghorn, J.L.","year":"1983","journal-title":"Psychopharmacology Bulletin"},{"key":"atypb10","doi-asserted-by":"publisher","DOI":"10.1007\/BF00393581"},{"key":"atypb11","volume-title":"[News Release] FDA Advisor y Committee Recommends New Clozaril Monitoring Guidelines, 16 July","author":"Fda","year":"1997"},{"key":"atypb12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1974.tb09706.x"},{"key":"atypb13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(75)90135-X"},{"key":"atypb14","first-page":"814","volume":"40","author":"Gross, V.H.","year":"1966","journal-title":"Wiener Medizinische Wochenschrift"},{"key":"atypb15","doi-asserted-by":"publisher","DOI":"10.1007\/BF00442551"},{"issue":"12","key":"atypb16","first-page":"22","volume":"60","author":"Hippius, H.","year":"1999","journal-title":"Jour nal of Clinical Psychiatr y"},{"key":"atypb17","volume-title":"Personal interview by author, 1\u20142 Aug. 2005","author":"Honigfeld, G.","year":"2005"},{"issue":"3","key":"atypb18","first-page":"276","volume":"10","author":"Hyde, T.M.","year":"1990","journal-title":"Neurology"},{"key":"atypb19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(75)90206-8"},{"key":"atypb20","first-page":"193","volume":"11","author":"Idanpaan-Heikkila, J.","year":"1977","journal-title":"Clinical Pharmacology"},{"key":"atypb21","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800330013001"},{"issue":"3","key":"atypb22","first-page":"6","volume":"17","author":"Leber, P.","year":"1981","journal-title":"Psychopharmacology Bulletin"},{"key":"atypb23","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1968.01740020009002"},{"key":"atypb24","doi-asserted-by":"publisher","DOI":"10.1001\/archneurpsyc.1954.02320380093011"},{"key":"atypb25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1979.tb00246.x"},{"key":"atypb26","first-page":"36","author":"Liang, B.C.","year":"2002","journal-title":"Hospital Physician"},{"key":"atypb27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688"},{"issue":"11","key":"atypb28","first-page":"1481","volume":"79","author":"Lindberg, G.L.","year":"1989","journal-title":"Health"},{"key":"atypb29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.4883.358-c"},{"issue":"7","key":"atypb30","first-page":"480","volume":"311","author":"Lurie, N.","year":"1984","journal-title":"Medicine"},{"key":"atypb31","first-page":"177","volume":"1","author":"Mattison, N.","year":"1986","journal-title":"Pharmaceutical Medicine"},{"key":"atypb32","first-page":"687","volume":"7","author":"Matz, R.","year":"1974","journal-title":"Current Therapeutic Research"},{"key":"atypb33","volume-title":"Marketing of Clozaril: improved safety or barrier to access, Subcommittee on Antitrust, Monopolies, and Business Rights","author":"Metzenbaum, H.","year":"1991"},{"key":"atypb34","doi-asserted-by":"publisher","DOI":"10.1038\/scientificamerican0785-31"},{"key":"atypb35","volume-title":"The Development of American Pharmacology","author":"Parascandola, J.","year":"1992"},{"key":"atypb36","volume-title":"Health Economics","author":"Phelps, C.","year":"1997","edition":"2"},{"issue":"2","key":"atypb37","first-page":"240","volume":"65","author":"Pisciotta, A.V.","year":"1965","journal-title":"Medicine"},{"key":"atypb38","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(58)90027-5"},{"key":"atypb39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1985.tb01268.x"},{"issue":"8","key":"atypb40","first-page":"870","volume":"41","author":"Reid, W.H.","year":"1990","journal-title":"Hospital and Community Psychiatry"},{"issue":"9","key":"atypb41","first-page":"166","volume":"55","author":"Reid, W.H.","year":"1994","journal-title":"Clinical Psychiatry"},{"key":"atypb42","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/17.2.247"},{"key":"atypb43","volume-title":"CPMS: Professionals' Guide to the Clozaril Patient Management System [original Sandoz Corp. marketing tool]","author":"Sandoz Pharmaceuticals Corp.","year":"1989"},{"key":"atypb44","unstructured":"Schmutz, J. and Eichenberger, E. (1982). Clozapine. In J. S. Bindra and D. Lednicer , Chronicles of Drug Discovery, Vol.1 (New York: John Wiley & Sons ), 39\u201459."},{"key":"atypb45","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1979.01780060047005"},{"key":"atypb46","volume-title":"A Histor y of Psychiatry:From the Era of the Asylum to the Age of Prozac","author":"Shorter, E.","year":"1997"},{"issue":"7","key":"atypb47","first-page":"679","volume":"16","author":"Simpson, G.M.","year":"1974","journal-title":"Current Therapeutic Research"},{"key":"atypb48","volume-title":"The Social Transfor mation of Amer ican Medicine","author":"Starr, P.","year":"1982"},{"key":"atypb49","doi-asserted-by":"publisher","DOI":"10.1016\/0010-440X(90)90038-T"},{"key":"atypb50","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1094311"},{"key":"atypb51","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.1.1.5"},{"key":"atypb52","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1991.03460190079024"},{"key":"atypb53","unstructured":"van Kammen, D.P. and Marder, S.R. (2000). Serotonin-dopamine antagonists. In B. Sadock and V. Sadock, Comprehensive Textbook of Psychiatry, Vol. II, 7th edn (Philadelphia: Lippincott Williams &Wilkins), 2455\u20146."},{"key":"atypb54","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000387375","volume":"5","author":"Van Rossum, J.M.","year":"1970","journal-title":"Pharmacopsychiatry"}],"container-title":["History of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0957154X07070335","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0957154X07070335","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:38:11Z","timestamp":1777451891000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0957154X07070335"}},"subtitle":["a review and analysis"],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["10.1177\/0957154X07070335"],"URL":"https:\/\/doi.org\/10.1177\/0957154x07070335","relation":{},"ISSN":["0957-154X","1740-2360"],"issn-type":[{"value":"0957-154X","type":"print"},{"value":"1740-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}